StockNews.com Begins Coverage on VolitionRx (NYSE:VNRX)

StockNews.com began coverage on shares of VolitionRx (NYSE:VNRX) in a research report released on Wednesday morning. The brokerage issued a sell rating on the stock.

A number of other brokerages also recently issued reports on VNRX. D. Boral Capital restated a “buy” rating and set a $5.00 price objective on shares of VolitionRx in a research report on Wednesday, April 30th. HC Wainwright initiated coverage on shares of VolitionRx in a research report on Tuesday, April 8th. They issued a “buy” rating and a $2.50 price objective on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, VolitionRx has a consensus rating of “Hold” and a consensus target price of $3.33.

VolitionRx Stock Performance

VNRX stock opened at $0.50 on Wednesday. The firm has a market cap of $50.39 million, a PE ratio of -1.39 and a beta of 1.00. The firm has a fifty day moving average price of $0.52 and a 200 day moving average price of $0.60. VolitionRx has a fifty-two week low of $0.42 and a fifty-two week high of $0.90.

Insider Activity

In other news, CEO Cameron John Reynolds bought 181,818 shares of the stock in a transaction on Wednesday, March 26th. The stock was acquired at an average cost of $0.55 per share, for a total transaction of $99,999.90. Following the acquisition, the chief executive officer now owns 2,299,222 shares of the company’s stock, valued at $1,264,572.10. This represents a 8.59 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 12.80% of the company’s stock.

Institutional Trading of VolitionRx

Institutional investors and hedge funds have recently made changes to their positions in the company. Two Sigma Securities LLC bought a new stake in shares of VolitionRx in the 4th quarter valued at about $29,000. Millennium Management LLC bought a new position in shares of VolitionRx during the fourth quarter valued at approximately $36,000. Northern Trust Corp raised its stake in VolitionRx by 32.0% in the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock worth $71,000 after buying an additional 28,579 shares in the last quarter. Geode Capital Management LLC raised its stake in VolitionRx by 15.1% in the third quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock worth $439,000 after buying an additional 95,900 shares in the last quarter. Finally, Lagoda Investment Management L.P. boosted its position in VolitionRx by 24.3% during the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock valued at $4,546,000 after acquiring an additional 1,481,000 shares in the last quarter. 8.09% of the stock is currently owned by institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.